NMRA vs. TARS, VIR, BCRX, FDMT, DNA, INBX, FUSN, SRRK, BEAM, and AUTL Should you be buying Neumora Therapeutics stock or one of its competitors? The main competitors of Neumora Therapeutics include Tarsus Pharmaceuticals (TARS), Vir Biotechnology (VIR), BioCryst Pharmaceuticals (BCRX), 4D Molecular Therapeutics (FDMT), Ginkgo Bioworks (DNA), Inhibrx (INBX), Fusion Pharmaceuticals (FUSN), Scholar Rock (SRRK), Beam Therapeutics (BEAM), and Autolus Therapeutics (AUTL). These companies are all part of the "biological products, except diagnostic" industry.
Tarsus Pharmaceuticals (NASDAQ:TARS ) and Neumora Therapeutics (NASDAQ:NMRA ) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, institutional ownership, media sentiment, dividends, valuation, earnings, profitability, community ranking and analyst recommendations.
Tarsus Pharmaceuticals' return on equity of 0.00% beat Neumora Therapeutics' return on equity.
In the previous week, Tarsus Pharmaceuticals had 17 more articles in the media than Neumora Therapeutics. MarketBeat recorded 18 mentions for Tarsus Pharmaceuticals and 1 mentions for Neumora Therapeutics. Neumora Therapeutics' average media sentiment score of 0.82 beat Tarsus Pharmaceuticals' score of -0.08 indicating that Tarsus Pharmaceuticals is being referred to more favorably in the media.
Tarsus Pharmaceuticals has higher revenue and earnings than Neumora Therapeutics.
Tarsus Pharmaceuticals presently has a consensus target price of $50.38, suggesting a potential upside of 31.73%. Neumora Therapeutics has a consensus target price of $22.57, suggesting a potential upside of 133.42%. Given Tarsus Pharmaceuticals' higher probable upside, analysts clearly believe Neumora Therapeutics is more favorable than Tarsus Pharmaceuticals.
90.0% of Tarsus Pharmaceuticals shares are held by institutional investors. Comparatively, 47.7% of Neumora Therapeutics shares are held by institutional investors. 11.5% of Tarsus Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Tarsus Pharmaceuticals received 32 more outperform votes than Neumora Therapeutics when rated by MarketBeat users. However, 90.91% of users gave Neumora Therapeutics an outperform vote while only 64.62% of users gave Tarsus Pharmaceuticals an outperform vote.
Summary Tarsus Pharmaceuticals beats Neumora Therapeutics on 9 of the 13 factors compared between the two stocks.
This chart shows the number of new MarketBeat users adding NMRA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Neumora Therapeutics Competitors List
Related Companies and Tools
